opc/vomiting

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 45 rezilta yo

Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In the management of pain, nausea and vomiting are some of the most distressing adverse effects induced by opioids. In the present study, we investigated the effect of the dopamine system-stabilizer aripiprazole on morphine-induced emesis. Morphine induced retching and vomiting in a dose-dependent

Functional Vomiting Treated Successfully with Aripiprazole in a Child with Autism Spectrum Disorder.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To report efficacy and safety of transitioning patients receiving intramuscular (IM) formulations of aripiprazole or haloperidol to their respective oral formulations. METHODS 448 agitated patients with schizophrenia (73%) or schizoaffective disorder (27%) were randomized to receive

Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Aripiprazole is widely used in the management of tic disorders (TDs), we aimed to assess the safety of aripiprazole for TDs in children and adolescents.A systematic literature review was performed in the databases of MEDLINE, Embase, the Cochrane Library

An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE This study evaluated flexible-dose pharmacokinetics, safety, and effectiveness of aripiprazole in children and adolescents with conduct disorder (CD). METHODS This open-label, 15-day, three-center study with an optional 36-month extension enrolled a total of 23 patients: 12 children (6-12

A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND This study followed manic or mixed bipolar I subjects for an additional 40 weeks after initial randomization to 12 weeks of lithium versus aripiprazole monotherapy. This is the only long-term, double-blind study comparing lithium and aripiprazole. METHODS Patients continued receiving

Risk assessment of isolated aripiprazole exposures and toxicities: a retrospective study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To characterize the clinical effects of acute isolated aripiprazole poisonings and to assess the toxic dose of this drug. METHODS All isolated acute aripiprazole exposures reported to a poison control system from January 2002 through September 2006 were retrospectively reviewed. Patients

A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To evaluate the efficacy and safety of aripiprazole versus placebo in preventing relapse of irritability symptoms associated with autistic disorder in pediatric patients. METHODS This multicenter, double-blind, randomized, placebo-controlled, relapse-prevention trial enrolled patients

Open labeled, randomized, switch-over study of two fixed doses (10/15mg) of aripiprazole : to evaluate its safety and efficacy in the treatment of Indian patients of schizophrenia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Aripiprazole is a new anti psychotic with a unique receptor binding profile that combines partial agonistic activity at D2 receptor and 5-HT 1A receptor and potent antagonism at 5-HT 2A receptor. This receptor profile makes it possible for it to act as a dopamine system stabilizer. Based on various

Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Antipsychotic augmentation is an effective treatment intervention for Obsessive Compulsive Disorder (OCD) patients resistant to Selective Serotonin Reuptake Inhibitors (SSRI) agents. This pilot study was conducted to evaluate the effectiveness and tolerability of Aripiprazole for the

Aripiprazole.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of aripiprazole are discussed. Aripiprazole is a third-generation antipsychotic agent indicated for use in the treatment of schizophrenia. Unlike other antipsychotics,

Atypical experience: a case series of pediatric aripiprazole exposures.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Aripiprazole is a new psychotropic agent that possesses a unique pharmacologic profile. The drug demonstrates mixed dopamine and serotonin agonist-antagonist activity and has been labeled a third-generation antipsychotic and dopamine-serotonin system stabilizer. Overdose experience is

Aripiprazole: An FDA Approved Bioactive Compound to treat schizophrenia-A Mini Review.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Aripiprazole,a synthetic compound, obtained by chemical modification of the structure of quinolinone is considered as an atypical antipsychotic drug. The present review is an attempt to summarize the updated information related to reported chemistry and pharmacology of

Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Small rodents (mice, rats) are the species of choice for evaluating the pharmacology of centrally acting compounds, such as antipsychotics, whereas toxicology data are routinely obtained from other species (rabbits, dogs, monkeys). Whilst there is a substantial number of "therapeutically relevant"

Aripiprazole-induced atrial fibrillation in a patient with concomitant risk factors.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Aripiprazole is an atypical antipsychotic drug with a polypharmacological mechanism of action and a favorable tolerability profile. Its major indications are schizophrenia and mania in adults and adolescents. Here we present the case of a 43-year-old Caucasian man with schizophrenia who developed

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye